## 2 Case Report  
The present case demonstrates the use of NIPP for wound healing disorders after tooth extraction following muco-periosteal flap in one patient receiving antiresorptive medication due to multiple myeloma. The plasma ONE Dental (plasma Medical Systems GmbH, Nievern, Germany), a DBD certified for intraoral use, was used with probe PS08 and PS12 at the highest intensity level (5) for 60 s per cm\({}^{2}\) (Figure 1a-d). The device operates on 12 V DC and modulates a high voltage of 18 kV, which generates an electric field at the tip of the probe. Thereby, the plasma is created. According to the company's information, the predominant reactive species generated by the plasma are NO, NO\({}_{2}\), and O\({}_{3}\). Detailed information about the device is shown in Table 1.  
The treatments were performed in accordance with the Declaration of Helsinki. The patient gave written informed consent to participate. Figure 1: Ambient-air NIPP was generated by a dielectric barrier discharge (**a**) plasma ONE Dental (plasma Medical Systems GmbH, Nievern, Germany); (**b**) instrument probe PS08; (**c**) instrument probe PS12; (**d**) principle of dielectric barrier discharge. A 63-year-old man presented to our clinic 2 weeks after all wisdom teeth and the first lower left molar had been removed under general anaesthesia (Figure 2a). Primary wound closure had been achieved for every wound area with a mucoperiosteal flap, which was necessary because the patient had been taking 4 mg of zoledronate intravenously every 3 months due to multiple myeloma diagnosed 2 years prior. Two weeks before the tooth removal, the drug had been discontinued by the oncologist for one dose. The bisphosphonate was resumed at the end of our therapy. In addition, the patient received clindamycin 600 mg three times daily for 8 days perioperative due to an existing penicillin allergy. The patient's medical history included hypertension and a heart attack suffered 4 years prior. \begin{table}
\begin{tabular}{c c} \hline \hline voltage & 7.9 V \\ \hline current & 240 mA \\ \hline power & 1.8 W \\ \hline converter pulse width & 10 \(\upmu\)s \\ \hline repetition frequency & 1220 Hz \\ \hline \end{tabular}
\end{table} 
Table 1: Plasma ONE Dental. Technical Data (intensity level 5, DBD mode). Figure 2: A 63-year-old patient receiving zoledronate for oncological reasons developed wound dehiscence 2 weeks after tooth extractions. (**a**) Panoramic X-ray at first presentation showing previous 4 years prior. extraction of all wisdom teeth and left lower first molar; (**b**) wound dehiscence of the area of the former left lower wisdom tooth at first presentation with complete epithelization after 35 days and follow-up after 6 months; (**c**) wound dehiscence of the area of the former first lower left molar at first presentation with complete epithelization after 42 days and follow-up after 6 months; (**d**) wound dehiscence of the area of the former right upper wisdom tooth at first presentation with complete epithelization after 49 days and follow-up after 6 month; (**e**) wound dehiscence of the area of the former right lower wisdom tooth at first presentation with complete epithelization after 49 days and follow-up after 6 months. On first presentation, all wounds except the site of the former upper left wisdom tooth presented as dehiscent with exposed bone (Figure 2b-e). The patient did not report any pain or sensory disturbances and denied having had radiotherapy in the head and neck area in the past. Since reoperation is not possible until about 6 to 12 weeks after dehiscence with stable wound conditions, the patient agreed to treat the wounds with NIPP in the intermediate period. In the following period, the patient presented himself weekly at our clinic. At each appointment, the wounds were irrigated with chlorhexidine (Kreussler Pharma, Wiesbaden, Germany) and photographic documentation was taken.